THE FIRST AND ONLY APPROVED BIOLOGIC TO SELECTIVELY TARGET BOTH IL-17A + IL-17F1-3

BIMZELX inhibits IL-17A + IL-17F, which can come from IL-23–dependent and IL-23–independent sources, both of which contribute to inflammation in psoriasis.4

Image
Simple teal, lime green, and purple illustration of how BIMZELX inhibits inflammation

Clinical relevance of mechanism of action is unknown. For illustrative purposes only.
IL=interleukin.

Image
Simple icon of a dark teal target with a light teal arrow in the bullseye

Targeting both IL-17A + IL-17F provides more inhibition of inflammation vs targeting IL-17A alone.3,5

 

 

WATCH BIMZELX IN ACTION

BIMZELX MOA video for HCPs
Image
arrow

EXPLORE RAPID, COMPLETE, AND MAINTAINED CLEARANCE FROM THE VERY FIRST DOSE1-3,6,7*

View Efficacy

*From the very first dose as measured at Week 4;
results were not immediate.

WANT MORE INFORMATION ABOUT BIMZELX?

Get updates and contact a sales representative

IMPORTANT SAFETY INFORMATION

Suicidal Ideation and Behavior

BIMZELX® (bimekizumab-bkzx) may increase the risk of suicidal ideation and behavior (SI/B). A causal association between treatment with BIMZELX and increased risk of SI/B has not been established. Prescribers should weigh the potential risks and benefits before using BIMZELX in patients with a history of severe depression or SI/B. Advise monitoring for the emergence or worsening of depression, suicidal ideation, or other mood changes. If such changes occur, advise to promptly seek medical attention, refer to a mental health professional as appropriate, and re-evaluate the risks and benefits of continuing treatment.

Infections

BIMZELX may increase the risk of infections. Do not initiate treatment with BIMZELX in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing BIMZELX. Instruct patients to seek medical advice if signs or symptoms suggestive of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer BIMZELX until the infection resolves.

Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with BIMZELX. Avoid the use of BIMZELX in patients with active TB infection. Initiate treatment of latent TB prior to administering BIMZELX. Consider anti-TB therapy prior to initiation of BIMZELX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Closely monitor patients for signs and symptoms of active TB during and after treatment.

Liver Biochemical Abnormalities

Elevated serum transaminases were reported in clinical trials with BIMZELX. Test liver enzymes, alkaline phosphatase and bilirubin at baseline, periodically during treatment with BIMZELX and according to routine patient management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt BIMZELX until a diagnosis of liver injury is excluded. Permanently discontinue use of BIMZELX in patients with causally associated combined elevations of transaminases and bilirubin. Avoid use of BIMZELX in patients with acute liver disease or cirrhosis.

Inflammatory Bowel Disease

Cases of inflammatory bowel disease (IBD) have been reported in patients treated with IL-17 inhibitors, including BIMZELX. Avoid use of BIMZELX in patients with active IBD. During BIMZELX treatment, monitor patients for signs and symptoms of IBD and discontinue treatment if new onset or worsening of signs and symptoms occurs.

Immunizations

Prior to initiating therapy with BIMZELX, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid the use of live vaccines in patients treated with BIMZELX.

MOST COMMON ADVERSE REACTIONS

Most common adverse reactions (≥ 1%) are upper respiratory infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, Herpes Simplex infections, acne, folliculitis, other Candida infections, and fatigue.


References:

1. BIMZELX® [prescribing information]. Smyrna, GA: UCB, Inc. 2. Gordon KB, et al. Lancet. 2021;397(10273):475-486. 3. Reich K, et al. N Engl J Med. 2021;385(2):142-152. 4. Cole S, et al. Front Immunol. 2020;11:585134. 5. Adams R, et al. Front Immunol. 2020;11:1894. 6. Reich K, et al. Lancet. 2021;397(10273):487-498. 7. Warren RB, et al. N Engl J Med. 2021;385(2):130-141.